Kentucky Administrative Regulations › Title 810 - PUBLIC PROTECTION CABINET - KENTUCKY HORSE RACING COMMISSION › Chapter 8 - Medication Guidelines › Section 810 KAR 8:025E - Drug, medication, and substance withdrawal guidelines

Current through Register Vol. 51, No. 1, July 1, 2024
RELATES TO:
				KRS
				230.215,
				230.225,
				230.240,
				230.260,
				230.265,
				230.290,
				230.320,
				230.370
NECESSITY, FUNCTION, AND CONFORMITY:
				KRS
				230.215(2) authorizes the
				Kentucky Horse Racing Commission to promulgate administrative regulations
				prescribing conditions under which all legitimate horse racing and wagering
				thereon is conducted in Kentucky.
				KRS
				230.240(2) requires the
				commission to promulgate administrative regulations restricting or prohibiting
				the administration of drugs or stimulants or other improper acts to horses
				prior to the horse participating in a race. This administrative regulation
				establishes the withdrawal guidelines for permitted drugs, medications, and
				substances that may be administered to race horses competing in
				Kentucky.
Section 1. The Kentucky
			 Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred;
			 Quarter Horse, Appaloosa, and Arabian.
(1)
			 This administrative regulation shall provide certain mandatory treatment
			 requirements, guidance, and advice on medication withdrawal
			 intervals.
(2) These withdrawal
			 guidelines regarding furosemide shall not apply to two (2) year-old or stakes
			 horses pursuant to
			 810
			 KAR 8:010 Section 6.
(3)
(a)
			 Unless otherwise specified in these withdrawal guidelines, KAR Title 810, or
			 KRS Chapter 230, the following withdrawal guidelines in this section are
			 voluntary and advisory. The guidelines are recommendations based on current
			 scientific knowledge that may change over time.
(b) A licensee may present evidence of full
			 compliance with these guidelines to the commission and the stewards as a
			 mitigating factor to be used in determining violations and penalties.
(c) These withdrawal interval guidelines
			 assume that administration of medications will be performed at doses that are
			 not greater than the manufacturer's maximum recommended dosage, or the dosage
			 recommended in this document. Medications administered at dosages above
			 manufacturer's recommendations, in compounded formulations, or in combination
			 with other medications or administration inside the withdrawal interval may
			 result in test sample concentrations above threshold concentrations that could
			 lead to positive test results and the imposition of penalties.
(d) The time of administration of an orally
			 administered substance, for the purposes of withdrawal interval, shall be
			 considered to be the time of complete ingestion of the medication by the horse
			 via eating or drinking.
(e) For
			 products containing multiple medications, the withdrawal time to be used should
			 be no less than the longest identified for any of the individual constituent
			 substances--even if that substance is not present in the highest concentration
			 in the product.
(f) Brand names of
			 medications, where applicable, are listed in parentheses following the generic
			 name of a drug.
(4)
(a) Withdrawal Guidelines. Furosemide shall
			 be administered pursuant to
			 810
			 KAR 8:010.
(b) The following substances may be
			 administered or applied up to the scheduled paddock time of the race in which
			 the horse is to compete:
1. Topical
			 applications, such as liniments, leg paints, salves, and ointments, which may
			 contain antibiotics or DMSO, but do not contain steroids, anesthetics, or any
			 other prohibited substances.
2. The
			 following substances may be administered up to twenty-four (24) hours prior to
			 the scheduled post time of the race in which the horse is to compete as long as
			 their use follows subsection (3) of this section:
a. Antibiotics, except those containing
			 prohibited drugs, such as Procaine;
b. Antiprotozoals, such as ponazuril
			 (Marquis), toltrazuril (Baycox), sulfamethoxa-zole/pyrimethamine
			 (Daraprim);
c. Antifungal agents,
			 such as Griseofulvin and Ketoconazole;
d. Certain inhalation agents that do not
			 exhibit bronchodilator properties, such as cromolyn sodium (Intal), and
			 acetylcysteine (Mucomyst);
e.
			 Cimetadine (Tagamet), orally at 20 mg/kg twice daily for 7 doses;
f. Electrolytes, Vitamins, and Minerals, via
			 IV, IM or oral administration;
g.
			 Any oral supplements or nutrients not containing drugs;
h. Hyaluronic Acid (Legend), via IV
			 administration;
i.
			 Misoprostol;
j. Non-Androgenic
			 Reproductive Hormones, such as HCG, Regumate and GnRH, in fillies and mares
			 only;
k. Omeprazole (Gastrogard),
			 orally at 2.2 g once daily for 4 days;
l. Polysulfated glycosaminoglycan (Adequan),
			 via IM administration;
m.
			 Proprionibacterium acnes suspension (Eqstim), or comparable immunostimulants,
			 excluding levamisole;
n. Ranitidine
			 (Zantac), orally at 8 mg/kg twice daily for 7 doses; and
o. Sucralfate.
3. Non-steroidal anti-inflammatory drugs
			 (NSAIDS):
a. Elected NSAID: Only one of the
			 following three NSAIDS may be administered up to the manufacturer's maximum
			 labeled dosage until forty-eight (48) hours prior to the scheduled post time of
			 the race in which the horse is to compete, as long as their use follows Section
			 1(3) of this administrative regulation and the requirements of
			 810
			 KAR 8:010.
(i)
			 Phenylbutazone (Butazolidin) 4.4 mg/kg, via IV administration only;
(ii) Flunixin Meglumine (Banamine) 1.1 mg/kg,
			 via IV administration only; and
(iii) Ketoprofen (Ketofen) 2.2 mg/kg, via IV
			 administration only.
b.
			 In accordance with the European Horserace Scientific Liaison Committee, the
			 following withdrawal intervals shall be observed for all NSAIDS, except for
			 those established in subpar-agraph 3.a. of this paragraph, for administration
			 prior to the scheduled post time of the race in which the horse is to compete,
			 as long as their use follows Section 1(3) of this administrative regulation:
(i) Flunixin Meglumine (Banamine) 1.1 mg/kg,
			 via IV administration: 6-day withdrawal interval;
(ii) Phenylbutazone (Butazolidin) 4.4 mg/kg,
			 via IV administration: 7-day withdrawal interval;
(iii) Ketoprofen (Ketofen) 2.2 mg/kg, via IV
			 administration: 4-day withdrawal interval;
(iv) Diclofenac Sodium Topical (Surpass
			 Cream), via a single, 5-inch application: 7- day withdrawal interval;
			 and
(v) Firocoxib (Equioxx) 0.1
			 mg/kg, via a single oral or IV dose, repeated daily administration: 15-day
			 withdrawal interval from date of last administration.
(5) The
			 following substances have a forty-eight (48) hour withdrawal guidance prior to
			 the scheduled post time of the race in which the horse is to compete as long as
			 their use follows Section 1(3) of this administrative regulation:
(a) Acepromazine (Promace), via IV
			 administration at 0.05 mg/kg;
(b)
			 Butorphanol (Torbugesic), via IV administration at 0.1 mg/kg;
(c) Cetirizine (Zyrtec), orally at 0.4 mg/kg
			 twice daily for 5 doses; although it is recommended that ivermectin should not
			 be administered within forty-eight (48) hours of a race if horse has been
			 administered cetirizine;
(d)
			 Dantrolene (Dantrium), via oral administration at 500 mg total dose;
(e) Detomidine (Dormosedan), via IV
			 administration at 5 mg single dose;
(f) DMSO via IV, oral, or topical
			 administration up to 60 ml
(g)
			 Glycopyrrolate (Robinol), via IV administration at 1 mg total dose;
(h) Guaifenesin, orally at 2 g twice daily
			 for 5 doses;
(i) Methocarbamol
			 (Robaxin-V), via single IV at 15 mg/kg;
(j) Procaine penicillin, via IM
			 administration at 17 mg/kg; and
(k)
			 Xylazine (Rompun), via IV administration at 200 mg single dose.
(6) The following substances shall
			 not be administered within forty-eight (48) hours of a race:
(a) Beta-2 agonists by inhalation, such as
			 terbutaline, salmeterol, and fenoterol;
(b) Ergot alkaloids, such as Ergonovine and
			 Methergine;
(c)
			 Ipratopium;
(d) Isoxsuprine;
			 and
(e) Pentoxyphylline
			 (Trental).
(7) The
			 following substances may be administered up to seventy-two (72) hours prior to
			 the scheduled post time of the race in which the horse is to compete as long as
			 their use follows Section 1(3) of this administrative regulation:
(a) Albuterol (Proventil) via inhalation at
			 720 mcg;
(b) Dexamethasone (Azium),
			 via oral, IV, IM administration at 0.05 mg/kg. However, if another
			 corticosteroid was administered systemically or intra-articularly, this
			 withdrawal guidance shall not apply and a minimum five (5) day withdrawal is
			 recommended;
(c) Lidocaine, via
			 subcutaneous administration at 200 mg total dose;
(d) Mepivacaine (Carbocaine), via
			 subcutaneous administration at 0.07 mg/kg; and
(e) Romifidine (Sedivet), via IV
			 administration at 50 mg.
(8) The following substances may be
			 administered up to ninety-six (96) hours prior to the scheduled post time of
			 the race in which the horse is to compete as long as their use follows Section
			 1(3) of this administrative regulation:
(a)
			 Hydroxyzine (Atarax); and
(b)
			 Phenytoin (Dilantin).
(9) Reserpine (Serpasil) may be administered
			 up to seven (7) days prior to the scheduled post time of the race in which the
			 horse is to compete as long as its use follows Section 1(3) of this
			 administrative regulation.
(10) The
			 use of an extra-corporeal shock wave therapy or radial pulse wave therapy
			 machine may be performed until ten (10) days prior to the scheduled post time
			 of the race in which the horse is to compete, as long as its use complies with
			 810
			 KAR 8:010.
(11) The following substance may be
			 administered up to twenty-one (21) days prior to the scheduled post time of the
			 race in which the horse is to compete, as long as its use follows Section 1(3)
			 of this administrative regulation, and its use complies with
			 810
			 KAR 8:010 Section 10: Clenbuterol (Ventipulmin),
			 orally up to 0.8 mcg/kg twice daily
(12) Any horse that has been treated with
			 therapeutic medications found in Section 1 of this administrative regulation
			 may, at the trainer's request and expense, and on permission of a commission
			 veterinarian, have samples of blood or urine collected by the commission
			 veterinarian for analysis by the commission laboratory prior to entry to race
			 in the state of Kentucky.
(a) As a condition
			 of this elective testing, the trainer shall be required to disclose the date
			 and time, dose, and route of administration of the substance for which
			 clearance testing is requested.
(b)
			 A report from the commission laboratory of a negative finding in this pre-race,
			 elective testing shall not provide a safe harbor for the owner, trainer,
			 veterinarian, or horse. A report from the commission laboratory of a positive
			 finding in a post-race sample shall be treated as a violation of KAR Title 810,
			 even if there was a negative finding by the commission laboratory in the
			 clearance testing sample.
(13) The following shall have a fourteen (14)
			 day stand down period for intra-articular injection. Any IA corticosteroid
			 injection within fourteen (14) days shall be a violation:
(a) Betamethasone, via IA administration at 9
			 mg total dose in a single articular space. Withdrawal time should be increased
			 for use of betamethasone products with a ratio of greater than 1:1
			 betamethasone acetate to betamethasone sodium phosphate. Intramuscular
			 administration is associated with substantially longer withdrawal
			 times.
(b) Isoflupredone (Predef
			 2x), via IA administration at 20 mg in a single joint space or 10 mg
			 subcutaneous.
(c) Methyprednisolone
			 (Depo-Medrol), via IA administration at a total dose of less than 100 mg in a
			 single articular space. Intramuscular administration is associated with
			 substantially longer withdrawal times and is not recommended, in accordance
			 with the Racing Medication and Testing Consortium. Clearance testing is
			 recommended in blood and urine prior to entry.
(d) Triamcinolone acetonide (Vetalog), via IA
			 administration at 9 mg total dose in a single articular space. Intramuscular
			 administration is associated with substantially longer withdrawal
			 times.
(14) It is
			 recommended that any horses receiving Fluphenazine (Prolixin) receive pre-race
			 clearance testing.
(15) Withdrawal
			 Guidelines Chart:
Substance
Brand Name
Recommended Minimum Withdrawal
Administration Specifications
Aceproma-zine
Prom-Ace
48 hours
0.05 mg/kg via IV administration
Acetylcyste-ine
Muco-myst
24 hours
Inhalation
Albuterol
Proventil
72 hours
720 mcg via inhalation
Beclome-thasone
Beclo-vent
24 hours
Inhalation only
Butorphanol
Tor-bugesic
48 hours
0.1 mg/kg via IV administration
Cetirizine
Zyrtec
48 hours
0.4 mg/ml orally twice daily for 5 doses
Cimetadine
Tagamet
24 hours
20 mg/kg orally twice daily for 7 doses
Clenbuterol
Ventip-ulmin
21 days
0.8 mcg/kg orally Pursuant to
							 810
							 KAR 8:010 Section 10, clenbuterol shall be prohibited
							 unless the prescription is made for a specific horse based on a specific
							 diagnosis. The veterinarian shall provide a copy of the treatment sheet to the
							 Equine Medical Director or de-signee for review within twenty-four (24) hours
							 of administration. A horse administered clenbuterol shall be placed on the
							 veterinarian's list for at least twenty-one (21) days after the last
							 administration. The horse shall meet all conditions for removal from the list,
							 including negative blood and urine sampling.
Cromolyn sodium
Intal
24 hours
Inhalation
Dantrolene
Dantri-um
48 hours
500 mg orally
Detomidine
Dor-mosedan
48 hours
5 mg via IV administration
Dexame-thasone
Azium
72 hours IV PO, with no other cortico-steroids
							 administered. 5 days if other corticosteroids have been administered.
IV, PO, IM, pursuant to the European Horserace
							 Scientific Liaison Committee.
DMSO
48 hours
Topical, IV, or oral administration up to 60
							 ml
Ergonovine
48 hours
No dose specified
Fenoterol
48 hours
Via inhalation, no dose specified
Furosemide 2-year-olds beginning in 2020
Stakes horses beginning in 2021
Salix
24 hours
Administration shall be prohibited at less than 24
							 hours, and limited to a maximum 500 mg single dose via IV administration
Furosemide
Salix
4 hours
150-500 mg single IV dose administered by KHRC
							 veterinarian. See
							 810
							 KAR 8:010 Section 6.
Guaifenesin
48 hours
2 g orally twice daily for 5 doses
Glyco-pyrrolate
Robinol
48 hours
1 mg
Griseofulvin
Fulvacin
24 hours
No dose specified
Hyaluronic Acid
Legend
24 hours
IV administration only; no dose specified
Hydroxyzine
Atarax
96 hours
No dose specified
Ipratropium
48 hours
Via inhalation, no dose specified
Isoxsuprine
Vasodi-lan
48 hours
No dose specified
Ketocona-zole
Nizoral
24 hours
No dose specified
Lidocaine
72 hours
200 mg total dose SQ
Mepivacaine
Carbo-caine
72 hours
0.07 mg/kg SQ
Methocar-bamol
Robaxin
48 hours
15 mg/kg single IV
Methyler-gonovine
Mether-gine
48 hours
No dose specified
Misoprostol
Cytotec
24 hours
No dose specified
Omeprazole
Gas-trogard
24 hours
2.2 g orally once daily for 4 days
Omeprazole
Gas-trogard
24 hours
2.2 g orally once daily for 4 days
Pentoxyfyl-line
Trental
48 hours
No dose specified
Phenytoin
Dilantin
96 hours
No dose specified
Ponazur-il/Diclazuril/S
							 ulfadiazine-Pyrimetham-ine
Mar-quis/Prot azil
24 hours
Oral
Procaine Penicillin
48 hours
17 mg/kg IM
Procaine penicillin treatments shall be reported to
							 the stewards no later than twenty-four (24) hours after the last injection is
							 administered. Horses so treated may be required to be under
							 commission-approved, continuous surveillance for the six-hour interval prior to
							 the post time for the race in which the horse is entered. The owner of the
							 horse shall be responsible for all costs associated with the surveillance.
							 Prospective surveillance arrangements shall be submitted to the stewards no
							 later than close of business on the day of entry.
PSGAG
Ad-equan
24 hours
Via IM administration
Ranitidine
Zantac
24 hours
8 mg/kg orally twice daily for 7 doses
Reserpine
Serpasil
7 days
No dose specified
Romifidine
Sedivet
72 hours
50 mg via IV administration
Salmeterol
48 hours
Via inhalation, no dose specified
Sucralfate
Carafate
24 hours
No dose specified
Terbutaline
48 hours
No dose specified
Xylazine
Rompun
48 hours
200 mg via IV administration
(16)
			 NSAID withdrawal guidelines chart:
Substance
Brand Name
Recommended Minimum Withdrawal
Administration Specifications
Phenylbut-azone
Butazol-idin
48 hours-single elected NSAID. If this is not the
							 single elected NSAID, then 7 days, pursuant to the European Horserace
							 Scientific Liaison Committee.
4.4 mg/kg via IV administration
Flunixin
Bana-mine
48 hours-single elected NSAID. If this is not the
							 single elected NSAID, then 6 days, pursuant to the European Horserace
							 Scientific Liaison Committee.
1.1 mg/kg via IV administration
Ketoprofen
Ketofen
48 hours-single elected NSAID, If this is not the
							 single elected NSAID, then 4 days, pursuant to the European Horserace
							 Scientific Liaison Committee.
2.2 mg/kg via IV administration
Diclofenac
Surpass
7 days, pursuant to the European Horserace Scientific
							 Liaison Committee.
5 inch ribbon of Surpass every 12 hours to one
							 site
Firocoxib
Equioxx
15 days, pursuant to the European Horserace
							 Scientific Liaison Committee.
0.1 mg/kg once daily for 4 days
(17)
			 Miscellaneous withdrawal guidelines chart:
Substance
Brand Name
Recommended Minimum Withdrawal
Administration Specifications
Anthemintics (except thi-azide products
72 hours
Non-androgenic reproductive hormones
Including HCG, Regu-mate, GnRH, in fillies and mares
							 only
24 hours
Proprionibacterium acnes suspension or comparable
							 immunostimulants
24 hours
Electrolytes, vitamins, minerals
24 hours
Via IV or IM administration
Antibiotics
24 hours
Any injectable other than furosemide
24 hours
810
							 KAR 8:010 specifically prohibits any injections at
							 less than 24 hours to post time for any substance.
Intra-articular injections, other than
							 corticosteroids
72 hours